Список литературы

1. Indran I.R., Huang Z., Khin L.W., Chan J., Viardot‐Foucault V., Yong E.L. Simplified 4‐item criteria for polycystic ovary syndrome: a bridge too far? // Clin Endocrinol (Oxf). 2018; 89(2): 202–211.

2. Torie Comeaux Plowden MD. M.P.H. Reproductive endocrinology and infertility. Eunice Kennedy Shriver National Institute of Child Health and Human Development; 2016.

3. Crespo R.P., Bachega TASS, Mendonça B.B., Gomes L.G. An update of genetic basis of PCOS pathogenesis // Arch Endocrinol Metab. 2018; 62: 352–361.

4. Chan J.L., Kar S., Vanky E. et al. Racial and ethnic differences in the prevalence of metabolic syndrome and its components of metabolic syndrome in women with polycystic ovary syndrome: a regional cross-sectional study // Am J Obstet Gynecol. 2017; 217: 189.e1–189.e8.

5. Balen A.H., Morley L.C., Misso M., Franks S., Legro R.S., Wijeyaratne C.N. et al. The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance // Hum Reprod Update. 2016; 22(6): 687–708.

6. Ansari R.M. Potential use of durian fruit (Durio zibenthinus Linn) as an adjunct to treat infertility in polycystic ovarian syndrome // J Integr Med. 2016; 14: 22–8.

7. Dokras A., Saini S., Gibson-Helm M., Schulkin J., Cooney L., Teede H. Gaps in knowledge among physicians regarding diagnostic criteria and management of polycystic ovary syndrome // Fertil Steril. 2017; 107: 1380–1386.e1.

8. Sha T., Wang X., Cheng W., Yan Y. A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF // Reprod Biomed Online. 2019 Aug; 39(2): 281–293. doi: 10.1016/j.rbmo.2019.03.203. Epub 2019 Mar 29.

9. Thakre N., Homburg R. A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome // Expert Rev Endocrinol Metab. 2019 Sep; 14(5): 315–319. doi: 10.1080/17446651.2019.1631797. Epub 2019 Jun 26.

10. Kamenov Z., Gateva A. Inositols in PCOS // Molecules. 2020 Nov 27; 25(23): 5566.

11. Gateva A., Kamenov Z. Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and/or Obesity. Obstet. Gynecol. Int. 2012, 2012, 1–11.

12. Morin-Papunen L.C., Vauhkonen I., Koivunen R.M., Ruokonen A., Tapanainen J.S. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome // Hum. Reprod. 2000; 15: 1266–1274.

13. Gateva A., Kamenov Z. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome // Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 164: 161–166.

14. Escobar-Morreale H., San Millan J. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol. Metabol. 2007; 18: 266–272.

15. Diamanti-Kandarakis E., Panidis D. Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): A prospective study of 634 women with PCOS // Clin. Endocrinol. 2007; 67: 735–742.

16. Nestler J.E., Jakubowicz D.J. Decreases in Ovarian Cytochrome P450c17α Activity and Serum Free Testosterone after Reduction of Insulin Secretion in Polycystic Ovary Syndrome // N. Engl. J. Med. 1996; 335: 617–623.

17. Nestler J.E., Jakubowicz D.J. Lean Women with Polycystic Ovary Syndrome Respond to Insulin Reduction With Decreases in Ovarian P450c17 alpha Activity and Serum Androgens. Obstet. Gynecol. Surv. 1998; 53: 289–291.

18. Cara J.F., Rosenfield R.L. Insulin-Like Growth Factor I and Insulin Potentiate Luteinizing Hormone-Induced Androgen Synthesis by Rat Ovarian Thecal-Interstitial Cells // Endocrinology. 1988; 123: 733–739.

19. Ek I., Arner P., Bergqvist A., Carlström K., Wahrenberg H. Impaired adipocyte lipolysis in nonobese women with the polycystic ovary syndrome: A possible link to insulin resistance? // J. Clin. Endocrinol. Metab. 1997; 82: 1147–1153.

20. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome // Diabetes. 1989; 38: 1165–1174.

21. Dunaif A., Segal K.R., Shelley D.R., Green G., Dobrjansky A., Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome // Diabetes. 1992; 41: 1257–1266.

22. Baillargeon J.P., Diamanti-Kandarakis E., Ostlund R.E. Jr., Apridonidze T., Iuorno M.J., Nestler J.E. Altered D-chiro-inositol urinary clearance in women with polycystic ovarian syndrome // Diabetes Care. 2006; 29: 300–305.

23. Rice S., Christoforidis N., Gadd C., Nikolaou D., Seyani L., Donaldson A., Margara R., Hardy K., Franks S. Impaired insulindependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries // Hum. Reprod. 2005; 20: 373–381.

24. Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L., Piltonen T., Norman R.J. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome // Fertil. Steril. 2018; 110: 364–379.

25. Rosenfield R.L., Ehrmann D.A. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited // Endocr. Rev. 2016; 37: 467–520.

26. Goodman N.F., Cobin R.H., Futterweit W., Glueck J.S., Legro R.S., Carmina E., American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). American association of clinical endocrinologists, American college of endocrinology, and androgen excess and PCOS society disease state clinical review: Guide to the best practices in the evaluation and treatment of polycystic ovary syndrome. Part 1 // Endocr. Pract. 2015; 21: 1291–1300.

27. Quigley M., Rakoff J., Yen S.S.C. Increased luteinising hormone sensitivity to dopamine inhibition in the polycystic ovary syndrome // J. Clin. Endocrinol. Metab. 1981; 52: 231.

28. Cumming D.C., Reid R.L., Quigley M.E., Rebar R.W., Yen S.S.C. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome // Clin. Endocrinol. 1984; 20: 643–648.

29. Barbieri R.L., Makris A., Randall R.W., Daniels G., Kistner R.W., Ryan K.J. Insulin Stimulates Androgen Accumulation in Incubations of Ovarian Stroma Obtained from Women with Hyperandrogenism // J. Clin. Endocrinol. Metab. 1986; 62: 904–910.

30. Dunkel L., Sorva R., Voutilainen R. Low levels of sex hormone-binding globulin in obese children // J. Pediatr. 1985; 107: 95–97.

31. Adashi E.Y., Hsueh A.J., Yen S.S. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells // Endocrinology. 1981; 108: 1441–1449.

32. Soldani R., Cagnacci A., Yen S.S. Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro // Eur. J. Endocrinol. 1994; 131: 641–645.

33. Poretsky L., Glover B., Laumas V., Kalin M., Dunaif A. The Effects of Experimental Hyperinsulinemia on Steroid Secretion, Ovarian [125 I] Insulin Binding, and Ovarian [125 I] Insulin-Like Growth-Factor I Binding in the Rat // Endocrinology. 1988; 122: 581–585.

34. Poretsky L., Cataldo N.A., Rosenwaks Z., Giudice L.C. The insulin-related ovarian regulatory system in health and disease // Endocr. Rev. 1999; 20: 535–582.

35. Franks S., Mason H., Willis D. Follicular dynamics in the polycystic ovary syndrome // Mol. Cell. Endocrinol. 2000; 163: 49–52.

36. Carmina E., Rosato F., Jannì A., Rizzo M., Longo R.A. Relative Prevalence of Different Androgen Excess Disorders in 950 Women Referred because of Clinical Hyperandrogenism // J. Clin. Endocrinol. Metab. 2006; 91: 2–6.

37. Dunaif A., Graf M., Mandeli J., Laumas V., Dobrjansky A. Characterization of Groups of Hyperaiidrogenic Women with Acanthosis Nigricans, Impaired Glucose Tolerance, and/or Hyperinsulinemia // J. Clin. Endocrinol. Metab. 1987; 65: 499–507.

38. Barber T.M., Wass J.A.H., McCarthy M.I., Franks S. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: Implications for the management of polycystic ovary syndrome // Clin. Endocrinol. 2007; 66: 513–517.

39. Bevilacqua A., Bizzarri M. Inositols in Insulin Signaling and Glucose Metabolism // Int. J. Endocrinol. 2018: 1–8.

40. Halsted C.H. Handbook of Vitamins: Nutritional, Biochemical, and Clinical Aspects // J. Nutr. 1987; 117: 397.

41. Beemster P., Groenen P., Steegers-Theunissen R. Involvement of Inositol in Reproduction // Nutr. Rev. 2002; 60: 80–87.

42. Chukwuma C.I., Ibrahim M.A., Islam S. Myo-inositol inhibits intestinal glucose absorption and promotes muscle glucose uptake: A dual approach study // J. Physiol. Biochem. 2016; 72: 791–801.

43. Cammarata P.R., Chen H.Q., Yang J., Yorio T. Modulation of myo-[3H]inositol uptake by glucose and sorbitol in cultured bovine lens epithelial cells. II. Characterization of high- and low-affinity myo-inositol transport sites. Investig. Ophthalmol. Vis. Sci. 1992; 33: 3572–3580.

44. Kollros P.E., Goldstein G.W., Betz A.L. Myo-inositol transport into endothelial cells derived from nervous system microvessels. Brain Res. 1990; 511: 259–264.

45. Unfer V., Nestler J.E., Kamenov Z.A., Prapas N., Facchinetti F. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials // Int. J. Endocrinol. 2016; 2016: 1–12.

46. Facchinetti F., Appetecchia M., Aragona C., Bevilacqua A., Espinola M.S.B., Bizzarri M., D’Anna R., Dewailly D., Diamanti-Kandarakis E., Marín I.H. et al. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: A further help for human reproduction and beyond. Expert Opin. Drug Metab. Toxicol. 2020; 16: 255–274.

47. Cabrera-Cruz H., Oróstica L., Plaza-Parrochia F., Torres-Pinto I., Romero C., Vega M. The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment // Am. J. Physiol. Metab. 2020; 318: 237–248.

48. Unfer V., Carlomagno G., Papaleo E., Vailati S., Candiani M., Baillargeon J.-P. Hyperinsulinemia Alters Myoinositol to d-chiroinositol Ratio in the Follicular Fluid of Patients With PCOS. Reprod. Sci. 2014; 21: 854–858.